---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-050372"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:37:40.479730+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio presents positive Phase 2a results for bempikibart in alopecia areata at AAD 2025

## Summary
- Bempikibart showed 16% mean SALT reduction at week 24 vs 2% placebo (p=0.045) in severe/very severe AA patients.
- Deepening responses observed post-dosing: 28% mean SALT reduction at week 36 in severe subset; two patients maintained response at week 55.
- Well-tolerated safety profile: no Grade 3+ related AEs, no related viral infections; PK and target engagement confirmed.
- OLE and SIGNAL-AA Part B (36-week dosing) to start 1H'25; Part B topline data expected 1H'26.
- All 12 responding patients maintained or improved hair growth post-treatment, median follow-up 41 weeks.

## SEC filing metadata
- accession: 0001193125-25-050372
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312525050372/0001193125-25-050372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312525050372/d931400d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-050372
- JSON: https://secwatch.observer/filing/0001193125-25-050372.json
- Plain text: https://secwatch.observer/filing/0001193125-25-050372.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.